Cambrex Corporation, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), is investing $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, IA plant. The 4,500 sq. ft. production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and have a total reactor capacity of 2,200 gallons, which will be made up from a range of 200, 500 and 1,000 gallon glass and Hastelloy vessels to manufacture...